In vitro antimicrobial activity and biofilm inhibitory effect of imipenem combined with tigecycline against mucoid Pseudomonas aeruginosa

doi:10.3969/j.issn.1673-8640.2020.06.002

Abstract

Abstract:

Objective To evaluate the inhibitory and biofilm inhibitory effect of imipenem combined with tigecycline on mucoid Pseudomonas aeruginosa（MPA） in vitro. Methods The minimum inhibitory concentration（MIC） of different concentrations of tigecycline and imipenem against 89 MPA isolates were determined by micro-broth dilution method. The checkerboard method was used to determine and classify the fractional inhibitory concentration index（FICI）,the time-killing curve was used to determine the combined effect,and the 96-well plate combined with crystal violet semi-quantitative staining was used to determine the biofilm inhibitory effect. Results The synergistic effect of tigecycline combined with imipenem on MPA was 46.07%（41 isolates）,partial synergistic effect was 14.6%（13 isolates）,and additive effect was 12.36%（11 isolates）,irrelevant effect was 26.97%（24 isolates）,and there was no antagonistic effect. At culturing for 24 h,the combined therapy showed >2 log₁₀ CFU/mL reduction in viable bacteria compared with tigecycline or imipenem alone. Compared with the use of tigecycline（1/4 MIC）,the combination of tigecycline with imipenem（1/4,1/2,1 MIC） reduced the counts of viable bacteria on each biofilm（P<0.05）. Compared with the use of imipenem（1/4 MIC）,the combination of imipenem with tigecycline（1/4,1/2,1 MIC） reduced the counts of viable bacteria on each biofilm（P<0.05）. Conclusions The combination of tigecycline with imipenem showed synergistic or partial synergistic effects on MPA. Combined therapy has higher antibacterial efficiency than that alone,and it has a certain enhancement effect on the inhibitory of biofilm.

Key words: Mucoid Pseudomonas aeruginosa, Biofilm, Time-killing curve, Tigecycline, Imipenem, Synergistic effect

CLC Number:

R378.99

ZHONG Feng, FENG Yi, ZHANG Jingjing, XU Yan, FANG Yongmei, TAO Xiubin, WU Jing. In vitro antimicrobial activity and biofilm inhibitory effect of imipenem combined with tigecycline against mucoid Pseudomonas aeruginosa[J]. Laboratory Medicine, 2020, 35(6): 519-523.

Figures/Tables 4

References 16

[1]	胡付品,郭燕,朱德妹,等. 2017年CHINET中国细菌耐药性监测[J]. 中国感染与化疗杂志,2018,18(3):241-251.
[2]	CHANG C Y.Surface sensing for biofilm formation in Pseudomonas aeruginosa[J]. Front Microbiol,2018,8:2671.
[3]	SAINI H,VADEKEETIL A,CHHIBBER S,et al.Azithromycin-ciprofloxacin-impregnated urinary catheters avert bacterial colonization,biofilm formation,and inflammation in a murine model of foreign-body-associated urinary tract infections caused by Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother,2017,61(3):e01906-e01916.
[4]	JAKOBSEN T H,BJARNSHOLT T,JENSEN PØ,et al.Targeting quorum sensing in Pseudomonas aeruginosa biofilms:current and emerging inhibitors[J]. Future Microbiology,2013,8(7):901-921.
[5]	WANG X,CAI Y,XING H,et al.Increased therapeutic efficacy of combination of azithromycin and ceftazidime on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection[J]. BMC Microbiol,2016,16(1):124.
[6]	SADER H S,FLAMM R K,JONES R N.Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide(2011)[J]. Diagn Microbiol Infect Dis,2013,76(2):217-221.
[7]	DZUL S P,THORNTON M M,HOHNE D N,et al.Contribution of the Klebsiella pneumoniae capsule to bacterial aggregate and biofilm microstructures[J]. Appl Environ Microbiol,2011,77(5):1777-1782.
[8]	Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-S20,CLSI,2015.
[9]	SAUER K,CAMPER A K,EHRLICH G D,et al.Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm[J]. J Bacteriol,2002,184(4):1140-1154.
[10]	MA L,WANG S,WANG D,et al.The roles of biofilm matrix polysaccharide Psl in mucoid Pseudomonas aeruginosa biofilms[J]. FEMS Immunol Med Microbiol,2012,65(2):377-380.
[11]	WIENS J R,VASIL A I,SCHURR M J,et al.Iron-regulated expression of alginate production,mucoid phenotype,and biofilm formation by Pseudomonas aeruginosa[J]. mBio,2014,5(1):e1010-e1013.
[12]	孟小斌,古汉福,雷南凤,等. 下呼吸道感染铜绿假单胞菌产绿脓菌素及生物膜形成能力与耐碳青霉烯类抗菌药物相关性分析[J]. 中华医院感染学杂志,2015,25(19):4336-4338.
[13]	MOREAU-MARQUIS S,STANTON B A,O'TOOLE G A. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway[J]. Pulm Pharmacol Ther,2008,21(4):595-599.
[14]	PETERSEN P J,LABTHAVIKUL P,JONES C H,et al.In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis[J]. J Antimicrob Chemother,2006,57(3):573-576.
[15]	SHAO J,CHENG H,WANG C.A phytoanticipin derivative,sodium houttuyfonate,induces in vitro synergistic effects with levofloxacin against biofilm formation by Pseudomonas aeruginosa[J]. Molecules,2012,17(9):11242-11254.
[16]	OZBEK B,MATARACI E.In vitro effectiveness of colistin,tigecycline and levofloxacin alone and combined with clarithromycin and/or heparin as lock solutions against embedded Acinetobacter baumannii strains[J]. J Antimicrob Chemother,2013,68(4):827-830.

抗菌药物	单用		联用
抗菌药物	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀
亚胺培南	1	2	0.125^*	0.25^*
替加环素	0.25	0.5	0.062 5^*	0.125^*

抗菌药物	单用		联用
抗菌药物	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀
亚胺培南	1	2	0.125^*	0.25^*
替加环素	0.25	0.5	0.062 5^*	0.125^*

亚胺培南MIC	替加环素MIC
亚胺培南MIC	0	1/4	1/2	1
0	0.261±0.006	0.214±0.005^*	0.211±0.009^*	0.136±0.004^*
1/4	0.248±0.005	0.189±0.008^*#	0.175±0.006^*#	0.129±0.01^*
1/2	0.227±0.004	0.164±0.005^*#	0.136±0.001^*#	0.125±0.005^*
1	0.128±0.007^#	0.13±0.003^#	0.126±0.006^#	0.126±0.004

亚胺培南MIC	替加环素MIC
亚胺培南MIC	0	1/4	1/2	1
0	0.261±0.006	0.214±0.005^*	0.211±0.009^*	0.136±0.004^*
1/4	0.248±0.005	0.189±0.008^*#	0.175±0.006^*#	0.129±0.01^*
1/2	0.227±0.004	0.164±0.005^*#	0.136±0.001^*#	0.125±0.005^*
1	0.128±0.007^#	0.13±0.003^#	0.126±0.006^#	0.126±0.004